Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | MPI | P34949 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | USP7 | Q93009 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13050024 | 0.83 | KDM4E (0.69) | KDM4EALDH1A1GAALMNAGLA | |
| SCHEMBL11813953 | 0.83 | KDM4E (0.69) | KDM4EALDH1A1GAALMNAGLA | |
| SCHEMBL27122992 | 0.81 | ALDH1A1 (0.50) | KDM4EALDH1A1GAALMNAGLA | |
| SCHEMBL14391863 | 0.81 | KDM4E (0.50) | KDM4EALDH1A1GAALMNAGLA | |
| SCHEMBL876113 | 0.80 | KDM4E (0.52) | KDM4EALDH1A1GAALMNAGLA | |
| SCHEMBL2149452 | 0.80 | GLA (0.49) | KDM4EALDH1A1GAALMNAGLA | |
| SCHEMBL13833755 | 0.78 | PKM (0.58) | KDM4EALDH1A1GAALMNAGLA | |
| SCHEMBL16175949 | 0.78 | KDM4E (0.47) | KDM4EALDH1A1GAALMNAGLA | |
| SCHEMBL909871 | 0.77 | GSK3B (0.48) | KDM4EALDH1A1GAALMNAGLA | |
| SCHEMBL13833582 | 0.76 | KDM4E (0.46) | KDM4EALDH1A1GAALMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | claimed |
| CN-114105986-B | Aromatic condensed ring diketone compound and preparation method and application thereof | 华东理工大学 | 2024-09-27 | — | — | CN | disclosed |
| CN-114105986-A | Aromatic condensed ring diketone compound and preparation method and application thereof | 华东理工大学 | 2022-03-01 | — | — | CN | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| EP-2730576-A2 | Anti-infective compounds | Institut Pasteur Korea (KR) | 2014-05-14 | — | — | EP | disclosed |
| EP-2730576-A2 | Anti-infective compounds | Institut Pasteur Korea (KR) | 2014-05-14 | — | — | EP | disclosed |
| EP-2619202-A1 | PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES | Pfizer Inc (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20130184294-A1 | Pyrimidones for Treatment of Potassium Channel Related Diseases | PFIZER INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | NO ZAESUNG (KR) | 2013-01-10 | — | — | US | disclosed |
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | NO ZAESUNG (KR) | 2013-01-10 | — | — | US | disclosed |
| WO-2012038850-A1 | PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES | PFIZER INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| WO-2011085990-A1 | ANTI - INFECTIVE PYRIDO (1,2 -A) PYRIMIDINES | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | WO | disclosed |
| EP-2310388-A2 | PYRIDOPYRIMIDINE COMPOUNDS AS ANTI-TUBERCULAR AGENTS | Institut Pasteur Korea (KR) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010003533-A2 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010003533-A2 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178077-A1 | Anti-infective compounds | RABGGTB, ELANE, SERPINB1 | KDM4E 4439/4885ALDH1A1 3932/4885GAA 949/4885 |
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | TYMS, TYMP, DCTPP1 | KDM4E 4036/4885ALDH1A1 2522/4885GAA 2894/4885 |
| US-20130184294-A1 | Pyrimidones for Treatment of Potassium Channel Related Diseases | KCNQ5, KCNQ1, KCNQ3 | KDM4E 2185/4885ALDH1A1 387/4885GAA 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.